Correction to: Nedosiran: First Approval.
作者信息
Syed Yahiya Y
机构信息
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
出版信息
Drugs. 2024 Feb;84(2):255. doi: 10.1007/s40265-024-01996-8.
Abstract
摘要
相似文献
1
Correction to: Nedosiran: First Approval.
Drugs. 2024 Feb;84(2):255. doi: 10.1007/s40265-024-01996-8.
2
Nedosiran: First Approval.
Drugs. 2023 Dec;83(18):1729-1733. doi: 10.1007/s40265-023-01976-4.
3
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Kidney Int. 2022 Mar;101(3):626-634. doi: 10.1016/j.kint.2021.08.015. Epub 2021 Sep 2.
4
Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Urolithiasis. 2023 Apr 28;51(1):80. doi: 10.1007/s00240-023-01453-3.
5
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Kidney Int. 2023 Jan;103(1):207-217. doi: 10.1016/j.kint.2022.07.025. Epub 2022 Aug 22.
6
Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies.
ACS Pharmacol Transl Sci. 2022 Sep 21;5(11):1007-1016. doi: 10.1021/acsptsci.2c00110. eCollection 2022 Nov 11.
7
Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
Urolithiasis. 2023 Jun 5;51(1):85. doi: 10.1007/s00240-023-01455-1.
8
Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report.
Urology. 2021 Oct;156:e147-e149. doi: 10.1016/j.urology.2021.03.014. Epub 2021 Mar 25.
9
A Case Report of Kidney-Only Transplantation in Primary Hyperoxaluria Type 1: A Novel Approach with the Use of Nedosiran.
Case Rep Nephrol Dial. 2023 Jul 7;13(1):63-69. doi: 10.1159/000531053. eCollection 2023 Jan-Dec.
10
Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria.
Kidney Int Rep. 2021 Feb 3;6(4):1088-1098. doi: 10.1016/j.ekir.2021.01.029. eCollection 2021 Apr.
引用本文的文献
1
Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1.
Clin Pharmacokinet. 2025 Jul 2. doi: 10.1007/s40262-025-01540-1.
2
Development of bioconjugate-based delivery systems for nucleic acids.
RNA. 2024 Dec 16;31(1):1-13. doi: 10.1261/rna.080273.124.
Zotero 插件